Platelet Aggregation Unchanged by Lipoprotein-Associated Phospholipase A2 Inhibition: Results from an In Vitro Study and Two Randomized Phase I Trials

Bonnie C. Shaddinger; Yanmei Xu; James H. Roger; Colin H. Macphee; Malcolm Handel; Charlotte A. Baidoo; Mindy Magee; John J. Lepore; Dennis L. Sprecher

doi:10.1371/journal.pone.0083094

Loading metrics

Open Access

Peer-reviewed

Research Article

Platelet Aggregation Unchanged by Lipoprotein-Associated Phospholipase A₂ Inhibition: Results from an In Vitro Study and Two Randomized Phase I Trials

Bonnie C. Shaddinger,

Affiliation Discovery Medicine, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America
⨯
Yanmei Xu,

Affiliation Discovery Biometrics, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America
⨯
James H. Roger,

Affiliation Research Statistics Unit, GlaxoSmithKline, Stockley Park, United Kingdom
⨯
Colin H. Macphee,

Affiliation Discovery Medicine, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America
⨯
Malcolm Handel,

Affiliation Janssen-Cilag Pty Ltd, Macquarie Park, New South Wales, Australia
⨯
Charlotte A. Baidoo,

Affiliation Discovery Biometrics, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America
⨯
Mindy Magee,

Affiliation Discovery Medicine, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America
⨯
John J. Lepore,

Affiliation Discovery Medicine, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America
⨯
Dennis L. Sprecher

* E-mail: Dennis.L.Sprecher@gsk.com

Affiliation Discovery Medicine, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America
⨯

Platelet Aggregation Unchanged by Lipoprotein-Associated Phospholipase A₂ Inhibition: Results from an In Vitro Study and Two Randomized Phase I Trials

Bonnie C. Shaddinger,
Yanmei Xu,
James H. Roger,
Colin H. Macphee,
Malcolm Handel,
Charlotte A. Baidoo,
Mindy Magee,
John J. Lepore,
Dennis L. Sprecher

Published: January 27, 2014
https://doi.org/10.1371/journal.pone.0083094

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Platelet aggregation
Is the Subject Area "Platelet aggregation" applicable to this article?

Thanks for your feedback.
Collagens
Is the Subject Area "Collagens" applicable to this article?

Thanks for your feedback.
Platelets
Is the Subject Area "Platelets" applicable to this article?

Thanks for your feedback.
Blood plasma
Is the Subject Area "Blood plasma" applicable to this article?

Thanks for your feedback.
Asthma
Is the Subject Area "Asthma" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Pharmacists
Is the Subject Area "Pharmacists" applicable to this article?

Thanks for your feedback.
Adults
Is the Subject Area "Adults" applicable to this article?

Thanks for your feedback.